This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.This is an open-label study to evaluate the hemostatic activity, pharmacokinetics and safety of OBI-1 (B-Domain deleted Recombinant Porcine fVIII) when administered by intravenous injection to control non-life and non-limb threatening bleeding episodes in congenital hemophilia A patients with an inhibitor to human fVIII.
Showing the most recent 10 out of 724 publications